Table 5 Comparison between the randomized controlled trials of erenumab for the prevention of migraine and the present study
From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
| Â | ARISE [26] | NCT02066415 [17] | STRIVE [18] | LIBERTY [19] | American real-life data [21] | Italian real-life data [22] | Present study | ||
|---|---|---|---|---|---|---|---|---|---|
General characteristics | |||||||||
 Migraine type | Episodic | Chronic | Episodic | Episodic | Chronic and episodic | 83% chronic, 17% episodic | 93.4% chronic, 6.6% episodic | ||
 Dose (mg) | 70 | 70 | 140 | 70 | 140 | 140 | 70 or 140 | 70 | 70 or 140 |
 No. of prior preventive treatment failures | < 2 (no response) | ≤3 (no response) | ≤2 (no response) | 2–4 | – | – | ≤2 | ||
 Follow-up duration, months | 3 | 3 | 6 | 3 | 2 | 2 | 6 | ||
 No. of treated patients | 286 | 191 | 190 | 317 | 319 | 121 | 100 | 78 (13 episodic, 65 chronic) | 89 |
Patient characteristics | |||||||||
 Female, % | 85.7 | 87 | 84 | 84.5 | 85.3 | 80 | 83 | 75% (EM), 80% (CM) | 87.6 |
 Mean age, years | 42 | 41.4 | 42.9 | 41.1 | 40.4 | 44.6 |  | 47.1 (EM), 47.6 (CM) | 46.8 |
 Mean migraine duration, years | 22 | 20.7 | 21.9 | – | – | – | – | 29.1 (EM), 30.2 (CM) | 28.2 |
 Medication overuse, % | – | 41 | 41 | – | – | – | – | 61.5 (EM), 84.6 (CM) | 71.9 |
 Prior preventive treatment failures, % | 87.3 | 67 | 66 | 40.1 | 36.4 | 100 | 100 | 100 | 100 |
 Mean MMDs at baseline | 8.1 | 17.9 | 17.8 | 8.3 | 8.3 | 9.2 | – | 10.9 (EM), 22.0 (CM) | 19.8 |
Outcomes | |||||||||
 MMD decrease, mean days | −2.9 | −6.6 | −6.6 | −3.2 | −3.7 | −1.8 | – | −7 (EM), −15 (CM) | −12.4 |
 Triptan use days decrease, mean days | −1.2 | −3.5 | −4.1 | −1.1 | −1.6 | −1.3 | – | – | −5.6 |
 50% responders, % | 39.3 | 40 | 41 | 43.3 | 50.0 | 30 | – | 100 (EM), 87.5 (CM) | 74.1 |
 Adverse events % | 48.1 | 44 | 47 | 57.3 | 55.5 | 55 | 34 | 1.3 | 22.5 |
 Serious adverse events % | 1.1 | 3 | 1 | 2.5 | 1.9 | 2 | 5 | – | 2.2 |